News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sagent Pharmaceuticals, Inc. Announces The Reintroduction Of Adenosine Injection, USP



4/21/2014 9:08:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SCHAUMBURG, Ill., April 21, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the reintroduction of Adenosine Injection, USP, an antiarrhythmic agent, now in improved prefilled plastic syringes. According to IMS, for the 12 months ending February 2014, the US market for Adenosine Injection, USP approximated $28 million. As with all products in Sagent's portfolio, Adenosine features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES